(R)-2-oxooxazolidine-4-carboxylic acid | 83841-00-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-oxooxazolidine-4-carboxylic acid
• 英文别名: (4R)-2-oxooxazolidine-4-carboxylic acid；(4R)-2-oxo-1,3-oxazolidine-4-carboxylic acid
• CAS: 83841-00-3
• 化学式: C₄H₅NO₄
• 分子量: 131.088
• InChiKey: XMFFFMBLTDERID-UWTATZPHSA-N

物化性质

• 密度：
  1.65g/cm3 at 20℃
• LogP：
  -3 at 20℃ and pH4.7-9
• 表面张力：
  70.3mN/m at 1g/L and 20℃
• 解离常数：
  2.69-2.71 at 20℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-2-oxooxazolidine-4-carboxylic acid 生成 L-丝氨酸
  参考文献：
  名称：

  Yokozeki, Kenzo; Majima, Eiji; Izawa, Kunisuke, Agricultural and Biological Chemistry, 1987, vol. 51, # 3, p. 963 - 964

  摘要：

  DOI：
• 作为产物：
  描述：

  potassium (4R)-2-oxooxazolidine-4-carboxylate 在 盐酸 、 4-甲基-2-戊酮 作用下， 生成 (R)-2-oxooxazolidine-4-carboxylic acid
  参考文献：
  名称：

  WO2023/232560

  摘要：

  公开号：

文献信息

• [EN] PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CYCLOSÉRINES SUBSTITUÉES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2015166094A1

  公开（公告）日：2015-11-05

  The present invention relates to processes for the preparation of substituted cycloserine compounds of formula (I) wherein R1 is C1-C8alkyl, C1-C8haloalkyl, C3-C6cycloalkyl,aryl or aryl substituted by one to five R11, or aryl-C1-C4alkylene or aryl-C1-C4alkylene substituted by one to five R11; and each R11 is independently C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, cyano or halogen; The invention also relates to intermediates produced by the processes. Compounds of formula (I) are useful intermediates for the production of compounds in the agricultural and pharmaceutical fields.

  本发明涉及制备式(I)的取代环丝氨酸化合物的过程，其中R1为C1-C8烷基，C1-C8卤代烷基，C3-C6环烷基，芳基或被1至5个R11取代的芳基，或芳基-C1-C4烷基或被1至5个R11取代的芳基-C1-C4烷基；每个R11独立地为C1-C4烷基，C1-C4卤代烷基，C1-C4烷氧基，C1-C4卤代烷氧基，氰基或卤素；该发明还涉及由这些过程产生的中间体。式(I)的化合物是在农业和制药领域生产化合物的有用中间体。
• Thiazolidone compounds and method of using the same as a vasodilator
  申请人：Sankyo Company, Limited

  公开号：US05298516A1

  公开（公告）日：1994-03-29

  Compounds of formula (I): ##STR1## wherein W represents a sulfur atom and X represents a group of formula --N(R.sup.1)--, or W represents a group of formula --N(R.sup.1)-- and X represents a sulfur atom; R.sup.1 is hydrogen, alkyl or aralkyl; R.sup.2 and R.sup.3 are each hydrogen, alkyl, aralkyl, aryl or aromatic heterocyclic; R.sup.4 is hydrogen, alkyl or aralkyl; and A is alkylene which is optionally substituted by carboxy; and pharmaceutically acceptable salts and esters thereof, have a valuable vasodilatory activity.

  式(I)的化合物：##STR1##其中W代表硫原子，X代表式--N(R.sup.1)--的基团，或者W代表式--N(R.sup.1)--的基团，X代表硫原子；R.sup.1是氢、烷基或芳基烷基；R.sup.2和R.sup.3分别是氢、烷基、芳基烷基、芳基或芳香杂环；R.sup.4是氢、烷基或芳基烷基；A是烷基，可以选择性地被羧基取代；以及其药学上可接受的盐和酯，具有有价值的血管扩张活性。
• Oxazolidinone compounds and method of using the same as a vasodilator
  申请人：Sankyo Company, Ltd.

  公开号：US05356918A1

  公开（公告）日：1994-10-18

  Compounds of formula (I): ##STR1## wherein W represents an oxygen atom and X represents a group of formula --N(R.sup.1)--; R.sup.1 is hydrogen, alkyl or aralkyl; R.sub.2 and R.sup.3 are each hydrogen, alkyl, aralkyl, aryl or aromatic heterocyclic; R.sup.4 is hydrogen, alkyl or aralkyl; and A is alkylene which is optionally substituted by carboxy; and pharmaceutically acceptable salts and esters thereof, have a valuable vasodilatory activity.

  公式（I）的化合物：##STR1## 其中W代表氧原子，X代表公式--N（R.sup.1）-的基团; R.sup.1是氢，烷基或芳基烷基; R.sub.2和R.sup.3分别是氢，烷基，芳基烷基，芳基或芳香族杂环; R.sup.4是氢，烷基或芳基烷基; A是可选地取代羧基的烷基;以及其药学上可接受的盐和酯，具有有价值的血管扩张活性。
• [EN] OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'OXADIAZOLE
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2019222431A9

  公开（公告）日：2020-10-22
• 6-Oxooxazolidine–quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR
  作者：Jiaan Shao、En Chen、Ke Shu、Wenteng Chen、Guolin Zhang、Yongping Yu

  DOI：10.1016/j.bmc.2016.04.046

  日期：2016.8

  Despite the remarkable benefits of gefitinib, the clinical efficacy is eventually diminished due to the acquired point mutations in the EGFR (T790M). To address this unmet medical need, we demonstrated a strategy to prepare a hybrid analogue consisting of the oxooxazolidine ring and the quinazoline scaffold and provided alternative noncovalent inhibitors targeting mutant forms of EGFR. Most of the derivatives displayed moderate to good anti-proliferative activity against gefitinib-resistant NCI-H1975. Some of them exhibited potent EGFR kinase inhibitory activities, especially on EGFR(T790M) and EGFR(L858R) kinases. SAR studies led to the identification of a hit 9a that can target both of the most common EGFR mutants: L858R and T790M. Also, 9a displayed weaker inhibitory against cancer cell lines with low level of EGFR expression and good chemical stability under different pH conditions. The work presented herein showed the potential for developing noncovalent inhibitors targeting EGFR mutants. (C) 2016 Published by Elsevier Ltd.